KRAS and non-small cell lung carcinoma: However, recent results from the phase 1 CodeBreak 100 trial (ClinicalTrials.gov Identifier: NCT03600883) with sotorasib (AMG 510), a first in class inhibitor of the KRAS G12C mutation, showed encouraging activity in heavily pre-treated advanced NSCLC and other solid tumours harbouring the KRAS G12C mutation (28).